有时，在肿瘤治疗中，少即是多！
PRABITAS：每两周一次的 TAS-102 + bevacizumab 在 OS 方面达到非劣效（11.3 vs 10.3 个月；HR 0.93），适用于难治性 mCRC。
≥3 级中性粒细胞减少症的发生率从 39% 降至 13%！
PFS 相当，毒性更低。这是一项实用、以患者为中心的进展。#ESMO26
64 浏览 · 1 赞 · 0 转发 · 0 回复
Iparomlimab and tuvonralimab (QL1706) plus chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (R/M CC): Results from a double-blind, randomized, placebo-controlled phase
https://esmocongress.esmo.orgLong-term follow-up of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Updated results of a phase 1 study
https://esmocongress.esmo.orgOutcomes with trifluridine/tipiracil plus bevacizumab across age groups in metastatic colorectal cancer: The BeTAS study
https://esmocongress.esmo.orgBiweekly versus conventional trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer: The pragmatic phase 3 PRABITAS trial
https://esmocongress.esmo.orgFinal overall survival (OS) results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase 3 trial of first-line atezolizumab (atezo), chemotherapy (CT) and bevacizumab (bev) for metastatic, persistent or recurrent cervic
https://esmocongress.esmo.org来源：Targeted Oncology · x.com